Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), Guangzhou, China.
Cancer Sci. 2021 Apr;112(4):1357-1368. doi: 10.1111/cas.14799. Epub 2021 Feb 21.
In recent years, the excellent curative effect of CD19-specific chimeric antigen receptor (CAR) T-cell therapy has brought hope to patients with relapsing or refractory B-cell hematological malignancies, however relapse after CAR T-cell infusion has hindered the widespread clinical application of this immunotherapy and targeted antigen-negative relapse has caused widespread concern. Consequently, strategies for increasing targeted antigens have been created. In addition to the most widely applied target, namely CD19, researchers have further explored the possibility of other targets, such as CD20, CD22, CD33, and CD123, and have tested a series of combination antigen CAR T-cell therapies. Here, we summarize the current preclinical and clinical studies of dual-target CAR T cells.
近年来，CD19 特异性嵌合抗原受体（CAR）T 细胞疗法的卓越疗效给复发或难治性 B 细胞血液恶性肿瘤患者带来了希望，然而 CAR T 细胞输注后的复发阻碍了这种免疫疗法的广泛临床应用，并且靶向抗原阴性复发引起了广泛关注。因此，人们已经创造了增加靶向抗原的策略。除了应用最广泛的靶点，即 CD19 外，研究人员还进一步探索了其他靶点的可能性，例如 CD20、CD22、CD33 和 CD123，并测试了一系列组合抗原 CAR T 细胞疗法。在这里，我们总结了双靶点 CAR T 细胞的当前临床前和临床研究。
